A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide With or Without Obatoclax Administered Every 3 Weeks to Patients With Extensive- Stage Small Cell Lung Cancer (ES-SCLC).

Trial Profile

A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide With or Without Obatoclax Administered Every 3 Weeks to Patients With Extensive- Stage Small Cell Lung Cancer (ES-SCLC).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Obatoclax (Primary) ; Carboplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Gemin X Pharmaceuticals
  • Most Recent Events

    • 18 Aug 2012 Planned number of patients changed from 188 to 196 as reported by European Clinical Trials Database.
    • 14 Feb 2012 Results from the phase I portion of this study have been published in full in the British Journal of Cancer.
    • 30 Jan 2012 Actual patient number changed from 165 to 218 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top